CClinicalTrials.gg
CompletedNCT03878134Updated Nov 1, 2023Results posted

Translational Development of Photon-counting CT Imaging

An interventional study of PHOTON COUNTING CT Scanner in Cancer, Inflammatory Disease and Vascular Diseases, sponsored by National Institutes of Health Clinical Center (CC). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by National Institutes of Health Clinical Center (CC) · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Using an investigational CT scanner which uses a new type of detector to capture X-rays, (a photon counting CT detector), the goal of this experimental study is to compare conventional CT images to CT images using the photon counting detector in patients undergoing CT scans for clinically indicated reasons. The main question it aims to answer is whether the images produced using the new detectors are superior in quality. Participants will undergo the clinically indicated CT images and the photon counting detector CT images of a limited area during the same examination time.

Read the detailed description

NIH develops new imaging techniques as one of its priorities for accelerating science, including methods for non-invasive patient assessments. Computed tomographic (CT) imaging is a mainstay of diagnostic imaging. The latest major technological advance is photon counting CT (PCCT) which uses a new x-ray detector that measures x-ray penetration of the body and the energy of each x-ray photon. NIH Clinical Center will use a prototype Siemens PCCT CounT systems built for clinical investigational use. The scanner can perform standard CT and PCCT imaging. In this protocol, NIH patients already enrolled in a clinical research protocol and who are referred to Radiology for diagnostic CT as part of that research may be enrolled in this study of PCCT. The diagnostic CT scan requested by their medical care team will be performed on the CounT scanner, providing the clinically indicated imaging, along with a single abbreviated PCCT exam of an organ or body part to support PCCT feasibility of the PCCT to provide better images in several small groups of patients with selected medical conditions. The data will be used to characterize quality of the PCCT images and to develop testable hypotheses and new diagnostic applications using PCCT capabilities.

Current CT systems, such as the Siemens SOMATOM Flash, have two x-ray tubes, each paired with an x-ray detector that measures total x-ray penetration of the patient and uses that information to create the images. The CounT scanner is a modified version of the Flash in which one of the two standard detectors has been replaced with a PCCT detector. The two imaging modes for the CounT scanner are (i) standard detector study as in a Flash scanner and (ii) PCCT scan. The patient scan will thus include clinically indicated radiation exposure with the standard detector and research radiation over a limited field with the PCCT detector. The CounT system is sited at the Clinical Center under a CRADA (Cooperative research and development agreement) with Siemens Medical Solutions.

Compared to current scanners, PCCT is expected to offer four major advantages:

  • lower radiation dose
  • greater spatial resolution
  • reduced imaging noise
  • x-ray energy discrimination

As a translational development protocol, all imaging studies are open-label and data may be analyzed as they are collected.

02

Conditions studied

  • Cancer
  • Inflammatory Disease
  • Vascular Diseases
  • Metabolic Bone Disease

Keywords

  • Photon Counting CT
  • Computed Tomography
  • Photon Counting Detectors
03

In context

Bone Diseases

261 studies on the registry are indexed under Bone Diseases; 49 are open to participants now.

This study's enrollment of 67 is above the median of 54 across 148 interventional studies indexed under Bone Diseases.

Browse Bone Diseases studies →

Lead sponsor

National Institutes of Health Clinical Center (CC) is the lead sponsor of 367 studies on the registry; 27 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 18 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • NIH patients currently on an NIH research protocol who are referred to RAD\&IS for CT examination as part of that research protocol
  • 18 years old or greater
  • Able to understand and sign informed consent

Exclusion criteria

EXCLUSION CRITERIA:

  • Studies that specifically require simultaneous dual source CT scan capability or where dual source CT scan is requested
  • Studies ordered for an emergency indication
  • Pregnant women. Subjects of child-bearing potential will undergo serum or urine pregnancy testing within 72 hours before examination. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing
  • Lactating women who are unable to stop breast feeding for 24 hours following the administration of contrast
  • Body weight >500 lbs (227 kg) or a body circumference that prevents the study subject from lying flat in the scanner
  • Patients who have undergone PCCT examination within the past year.
  • Any contraindications that the research team identifies from the subject, RAD\&IS CT questionnaires, and/or History and Assessment
  • Employees or staff supervised by the Principal Investigator or an Associate will not be recruited to participate
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Patients undergoing conventional and Photon Counting CT scan on the investigational scanner

    18 and older patients who undergo the conventional CT scan and the photon counting CT (PCCT) scan. Patient's images on the conventional scanner provide internal control to compare to the PCCT images.

    Device: PHOTON COUNTING CT Scanner

Interventions

  • DevicePHOTON COUNTING CT Scanner

    Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.

06

What researchers measure

Primary outcomes

  1. Mean Difference in Diagnostic Image Quality Grading of Photon Counting CT vs Conventional CT Images.

    Mean difference in relative image quality grading of CT images using Photon counting detectors vs. conventional detectors in group of patients with various clinical conditions. Scale name "Visual grading analysis (VGA)" . Expert radiologist observers compare the relative grades of the images from the PCCT to the grades of the same patient's reference images from conventional CT acquired at the same time. The visual grading scale incorporates technical factors in the acquisition and image display (such as contrast, noise and presence of artifacts and post processing). Grading is based on 5 point scale. 1- lowest image quality, 5- highest image quality. 5 is a better result. Scale as follows: 1 Images not usable- severe limitations for diagnostic use, 2 Limited -some loss of information, significant limitations for clinical use, 3 Adequate -moderate limitations for diagnostic use, 4 Good-minimal limitations for clinical use, 5 Excellent- no limitations for clinical diagnosis.

    Time frame: 2 years and 3 months, 27 months

07

Results

Posted Sep 21, 2023
Limitations and caveats
The PCCT detector and investigational CT scanner itself were in development at the time of the trial. The detector and scanner platform has been developed by industry since this time. These results are not predictive of the performance of the FDA approved PCCT scanner which was approved in October 2021.

Participant flow

Patients referred for diagnostic CT scan with clinical history or at risk status for conditions such as urologic cancers, lung cancers, as well as patients with conditions such as inflammatory lung or soft tissue diseases, arterial disorders of small vessels, or metabolic bone disease.

Participant flow — Overall Study
MilestonePatients Enrolled to Receive the Intervention PCCT CT Scan
Started67
Completed56
Not completed11
Withdrew: Scanner downtime or scheduling conflict11

Outcome measures

PrimaryMean Difference in Diagnostic Image Quality Grading of Photon Counting CT vs Conventional CT Images.

Mean difference in relative image quality grading of CT images using Photon counting detectors vs. conventional detectors in group of patients with various clinical conditions. Scale name "Visual grading analysis (VGA)" . Expert radiologist observers compare the relative grades of the images from the PCCT to the grades of the same patient's reference images from conventional CT acquired at the same time. The visual grading scale incorporates technical factors in the acquisition and image display (such as contrast, noise and presence of artifacts and post processing). Grading is based on 5 point scale. 1- lowest image quality, 5- highest image quality. 5 is a better result. Scale as follows: 1 Images not usable- severe limitations for diagnostic use, 2 Limited -some loss of information, significant limitations for clinical use, 3 Adequate -moderate limitations for diagnostic use, 4 Good-minimal limitations for clinical use, 5 Excellent- no limitations for clinical diagnosis.

Time frame:
2 years and 3 months, 27 months
Reported as:
Mean · score on a scale
Mean Difference in Diagnostic Image Quality Grading of Photon Counting CT vs Conventional CT Images.
score on a scalePatients Enrolled in Protocol
Mean Difference in Diagnostic Image Quality Grading of Photon Counting CT vs Conventional CT Images.0.947368421 ± 0.478877133

Adverse events

Collected over 24 hours unanticipated events related to the device are apparent at the time of scanning. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Receiving the Intervention PCCT CT Scan0/56 (0%)0/56 (0%)0/56 (0%)

Baseline characteristics

11 patients could not be scanned on the PCCT investigational scanner after being enrolled due to scanner downtime.

Age, Continuous
Age, Continuous(years)Patients Referred for Diagnostic CT Scans
Mean52 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Patients Referred for Diagnostic CT Scans
Female39
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients Referred for Diagnostic CT Scans
Hispanic or Latino3
Not Hispanic or Latino64
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients Referred for Diagnostic CT Scans
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American7
White52
More than one race0
Unknown or Not Reported2
Adults referred for diagnostic CT scan
Adults referred for diagnostic CT scan(Participants)Patients Referred for Diagnostic CT Scans
Count of participants67
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Symons R, Pourmorteza A, Sandfort V, Ahlman MA, Cropper T, Mallek M, Kappler S, Ulzheimer S, Mahesh M, Jones EC, Malayeri AA, Folio LR, Bluemke DA. Feasibility of Dose-reduced Chest CT with Photon-counting Detectors: Initial Results in Humans. Radiology. 2017 Dec;285(3):980-989. doi: 10.1148/radiol.2017162587. Epub 2017 Jul 28. PubMed 28753389 ↗
  • Pourmorteza A, Symons R, Henning A, Ulzheimer S, Bluemke DA. Dose Efficiency of Quarter-Millimeter Photon-Counting Computed Tomography: First-in-Human Results. Invest Radiol. 2018 Jun;53(6):365-372. doi: 10.1097/RLI.0000000000000463. PubMed 29595753 ↗
  • Pourmorteza A, Symons R, Reich DS, Bagheri M, Cork TE, Kappler S, Ulzheimer S, Bluemke DA. Photon-Counting CT of the Brain: In Vivo Human Results and Image-Quality Assessment. AJNR Am J Neuroradiol. 2017 Dec;38(12):2257-2263. doi: 10.3174/ajnr.A5402. Epub 2017 Oct 5. PubMed 28982793 ↗

Study documents

  • Study protocol · Apr 23, 2019
  • Statistical analysis plan · Aug 22, 2023
  • Informed consent form · Apr 3, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03878134
Lead sponsor
National Institutes of Health Clinical Center (CC)
Responsible party
Sponsor
First posted
Mar 18, 2019
Start date
Oct 1, 2019
Primary completion
Jan 18, 2022
Completion
Jan 18, 2022
Results posted
Sep 21, 2023
Last update
Nov 1, 2023

Study contacts

Elizabeth C Jones, M.D.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion